In vitro susceptibility testing in fungi: A global perspective on a variety of methods

Mycoses

Volumn 53, Issue 1, 2010, Pages 1-11

  Lass Flörl, Cornelia ^a   Perkhofer, Susanne ^a   Mayr, Astrid ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

EUCAST; In vitro and in vivo resistance; In vitro antifungal susceptibility testing

Indexed keywords

AGAR; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

AGAR DIFFUSION; ANTIFUNGAL RESISTANCE; ASPERGILLUS; BROTH DILUTION; CANDIDA; DISK DIFFUSION; DRUG SENSITIVITY; EPSILOMETER TEST; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR RECOGNITION; MYCOSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; FUNGI; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOSES;

ASPERGILLUS; CANDIDA; FUNGI;

EID: 72349094324     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01813.x     Document Type: Review

References (106)

1. Patterson T. Advances and challenges in management of invasive mycoses. Lancet 2005 17 : 1013 1025.
2. Neofytos D, Horn D, Anaissie E et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009 48 : 265 273.
3. Kanafani Z, Perfect J. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008 46 : 120 128.
4. Johnson E. Issues in antifungal susceptibility testing. J Antimicrob Chemother 2008 61 : i13 i18.
5. Weiler S, Lass-Flörl C, Auberger J, Bellmann-Weiler R, Stein M, Joannidis M. Triazole-resistant candidaemia following posaconazole exposure. Int J Antimicrob Agents 2008 33 : 494 495.
6. Auberger J, Lass-Flörl C, Clausen J et al. First case of breakthrough pulmonary Aspergillus niveus infection in a patient after allogeneic hematopoietic stem cell transplantation. Diagn Microbiol Infect Dis 2008 62 : 336 339.
7. Howard S, Webster I, Moore BC et al. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 2006 28 : 450 453.
8. Snelders E, van der Lee H, Kuijper J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. Plos Med 2009 5 : e 219.
9. Gulshan K, Moye-Rowley W. Multidrug resistance in fungi. Eukaryot Cell 2007 6 : 1933 1942.
10. Moore C, Walls C, Denning D. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 2000 44 : 441 443.
11. Pavie J, Lacroix C, Hermoso D et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 2005 43 : 4902 4904.
12. Warnock D, Arthington-Skaggs BA, Ren-Kai L. Antifungal drug susceptibility testing and resistance in Aspergillus. Drug Resist Update 1999 2 : 326 334.
13. Gehrt A, Peter J, Pizzo P, Walsh T. Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method. J Clin Microbiol 1995 33 : 1302 1307.
14. Meletiadis J, Meis J, Mouton J, Verweij PE. Analysis of growth characteristics of filamentous fungi in different nutrient media. J Clin Microbiol 2001 39 : 478 484.
15. Gomez-Lopez A, Aberkane A, Petrikkou E, Mellado E, Rodriguez-Tudela JL. Analysis of the influence of tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp. J Clin Microbiol 2005 43 : 1251 1255.
16. Rodriguez-Tudela JL, Chryssanthou E, Petrikkou E, Mosquera J, Dennind DW, Cuenza-Estrella M. Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. J Clin Microbiol 2003 41 : 5236 5237.
17. Aberkane A, Cuenca-Estrella M, Gomez-Lopez A et al. Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi. J Antimicrob Chemother 2002 50 : 719 722.
18. Petrikkou E, Rodriguez-Tudela JL, Cuenca-Estrella M, Gomez A, Molleja A, Mellado E. Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans. J Clin Microbiol 2001 39 : 1345 1347.
19. Clinical Laboratory Standard Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Approved standard. M38-A2. Wayne, PA : Clinical Laboratory Standard Institute, 2008.
20. Clinical Laboratory Standard Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard, M27-A3. Wayne, PA : Clinical Laboratory Standard Institute, 2008.
21. Subcommittee of Antifungal Susceptibility Testing of the European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases. EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008 14 : 398 405.
22. Subcommittee of Antifungal Susceptibility Testing of the European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical Microbiology Infectious Diseases. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. http://wwwescmidorg 2007.
23. Cuenca-Estrella M, Arenderup M, Chryssanthou E et al. Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect 2007 13 : 1018 1022.
24. Espinel-Ingroff A, Bartlett M, Bowden R et al. A multicenter evaluation of the standardization of antifungal susceptibility testing for filamentous fungi. J Clin Microbiol 2004 35 : 139 143.
25. European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). EUCAST technical note on fluconazole. Clin Microbiol Infect 2008 14 : 193 195.
26. Arendrup M, Kahlmeter G, Rodriguez-Tudela JL, Donnelly JP. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob Agents Chemother 2009 53 : 1628 1629.
27. Subcommittee of Antifungal Susceptibility Testing of the European Committee for Antimicrobial Susceptibility Testing of the European Society of Clinical Microbiology and Infectious Diseases. EUCAST technical note on voriconazole. Clin Microbiol Infect 2008 14 : 985 987.
28. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006 19 : 435 447.
29. Pfaller M, Diekema DJ, Rex J et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006 44 : 819 826.
30. Pfaller M, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 2008 46 : 2620 2629.
31. Lass-Flörl C, Cuenca-Estrella M, Denning D, Rodriguez-Tudela J. Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology. Med Mycol 2006 44 (Suppl 1 319 325.
32. Chryssanthou E, Cuenca-Estrella M. Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp. Clin Microbiol Infect 2006 12 : 901 904.
33. Pfaller M, Diekema DJ, Ghannoum A et al. Wild type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods. J Clin Microbiol 2009 47 : 3142 3146.
34. Rodriguez-Tudela J, Cazar-Fuoli L, Mellado E, Astruey-Izquierdo A, Monzon A, Cuenca-Estrella M. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008 52 : 2468 2472.
35. Lass-Flörl C, Griff K, Mayr A et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005 131 : 201 207.
36. Kartsonis N, Nielsen J, Douglas C. Caspofungin: the first in a new class of antifungal agents. Drug Resist Update 2003 6 : 197 218.
37. Kurtz M, Heath I, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-ß-d-glucan synthase. Antimicrob Agents Chemother 1994 38 : 1480 1489.
38. Arikan S, Lozano-Chiu M, Paetznick V, Rex J. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother 2001 45 : 327 330.
39. Odds F, Motyl M, Andrade R et al. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol 2004 42 : 3475 3482.
40. Espinel-Ingroff A. Utility of mould susceptibility testing. Curr Opin Infect Dis 2003 16 : 527 532.
41. Lass-Flörl C, Nagl M, Speth C, Ulmer H, Dierich MP, Würzner R. Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining. Antimicrob Agents Chemother 2001 45 : 124 128.
42. Clinical Laboratory Standard Institute. Methods for Antifungal Disk Diffusion Susceptibility Testing of Yeasts: Approved Standard M44-A. Wayne, PA : Clinical Laboratory Standard Institute, 2004.
43. Pfaller M, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006 44 : 760 763.
44. Rex JH, Pfaller M, Rinaldi MG, Polak A, Galgani NJ. Antifungal susceptibility testing. Clin Microbiol Rev 1993 6 : 367 381.
45. Therese K, Bagyalakshmi R, Madhavan N, Deepa P. In-vitro susceptibility testing by agar dilution method to determine the minimum inhibitory concentrations of amphotericin B, fluconazole and ketoconazole against ocular fungal isolates. Indian J Med Microbiol 2007 24 : 273 279.
46. Espinel-Ingroff A, Arthington-Skaggs BA, Igbal N et al. A multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin-B and caspofungin. J Clin Microbiol 2007 45 : 1811 1820.
47. Messer SA, Diekema DJ, Hollis RJ et al. Evaluation of disk diffusion and Etest compared to broth microdilution for antifungal susceptibility testing of posaconazole against clinical isolates of filamentous fungi. J Clin Microbiol 2007 45 : 1322 1324.
48. Pfaller M, Messer SA, Mills K, Bolmstrom A. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol 2000 38 : 3361.
49. Pfaller M, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Diekema DJ. Evaluation of the etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. J Clin Microbiol 2004 42 : 4977 4979.
50. Szekely A, Johnson E, Warnock D. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of moulds. J Clin Microbiol 1999 37 : 1483.
51. Alexander BD, Byrne T, Smith K et al. Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol 2007 45 : 698 706.
52. Pfaller M, Chaturvedi V, Diekema DJ et al. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J Clin Microbiol 2008 46 : 2155 2159.
53. Avolio M, Grosso S, Bruschetta G, De Rosa R, Camporese A. Direct antifungal susceptibility testing of positive Candida blood cultures by sensititre YeastOne. New Microbiol 2009 32 : 179 184.
54. Guinea J, Pelaez T, Alcala L, Bouza E. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus. Diagn Microbiol Infect Dis 2006 56 : 53 55.
55. Castro C, Serrano MC, Flores B, Espinel-Ingroff A, Martin-Mazuelos E. Comparison of the Sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38-A method to determine the activity of voriconazole against clinical isolates of Aspergillus spp. J Clin Microbiol 2004 42 : 4358 4360. (Pubitemid 39296177)
56. Martin-Mazuelos E, Peman J, Valverde A, Chaves M, Serrano MC, Canton E. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J Antimicrob Chemother 2003 52 : 365 370.
57. Torres-Rodriguez J, Alvarado-Ramirez E. In vitro susceptibilities to yeasts using the ATB FUNGUS 2 method, compared with Sensititre Yeast One and standard CLSI (NCCLS) M27-A2 methods. J Antimicrob Chemother 2007 60 : 658 661.
58. Eraso E, Ruesqa M, Villar-Vidal M, Carrillo-Muñoz A, Espinel-Ingroff A, Quindos G. Comparative evaluation of ATB Fungus 2 and Sensititre YeastOne panels for testing in vitro Candida antifungal susceptibility. Rev Iberoam Micol 2008 25 : 3 6.
59. Pfaller M, Diekema DJ, Procop GW, Rinaldi M. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol 2007 45 : 3522 3528. (Pubitemid 350156842)
60. Pfaller M, Diekema DJ, Procop GW, Rinaldi M. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol 2007 45 : 802.
61. Posteraro B, Martucci R, la Sorda M et al. Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata. J Clin Microbiol 2009 47 : 1927 1930.
62. Pfaller M, Arikan S, Lozano-Chiu M et al. Clinical evaluation of the ASTY colorimetric microdilution panel for antifungal susceptibility testing. J Clin Microbiol 1998 36 : 2609 2612.
63. Kalkanci A, Mekha N, Poonwan N, Makimura K, Sugita T. Comparative evaluation of Trichosporon asahii susceptibility using ASTY colorimetric microdilution and CLSI M27-A2 broth microdilution reference methods. Microbiol Immunol 2008 52 : 435 439.
64. Jahn B, Stuben A, Bhakdi S. Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione-augmented 3-(4,5-dimethyl-2- thiazolyl)-2,5- diphenyl-2H-tetrazolium bromide and Alamar blue tests. J Clin Microbiol 1996 34 : 2039 2041.
65. Meletiadis J, Meis JFGM, Mouton JW, Donnelly JP, Verweij PE. Comparison of NCCLS and 3-(4,5-Dimethyl-2-Thiazyl)-2,5-Diphenyl-2H-Tetrazolium Bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J Clin Microbiol 2000 38 : 2949 2954.
66. Vale-Silvia L, Buchta V. Antifungal susceptibility testing by flow cytometry: is it the future? Mycoses 2006 49 : 261 273.
67. Ramani R, Gangwar M, Chaturvedi V. Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and ocmparison of mode of action of voriconazole vis-a-vis amphotericin B and itraconazole. Antimicrob Agents Chemother 2003 47 : 3627 3629.
68. Balajee SA, Marr KA. Conidial vability assay for rapid susceptibility testing of Aspergillus species. J Clin Microbiol 2002 40 : 2741 2745.
69. Arthington-Skaggs BA, Jradi H, Desai T, Morrison CJ. Quantitation of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicans. J Clin Microbiol 1999 37 : 3332 3337.
70. Steinbach W, Stevens D, Dennind DW. Combination and sequential therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1996 to 2001. Clin Infect Dis 2003 37 : S188 S224.
71. Johnson M, MacDougall C, Ostrosky-Zeichner L, Perfect J, Rex J. Combination antifungal therapy. Antimicrob Agents Chemother 2004 48 : 693 715.
72. Kiraz N, Dag I, Yamac M, Kiremitci A, Kasifoglu N, Akgun Y. Antifungal activity of caspofungin in combination with amphotericin B against Candida glabrata: comparison of disk diffusion, Etest, and time-kill methods. Antimicrobial Agents and Chemptherapy 2009 53 : 788 790.
73. Lewis R, Diekema DJ, Messer SA, Pfaller M, Klepser ME. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. Journal of Antimicrobial Agents 2002 49 : 345 351.
74. Pfaller M, Sheehan D, Rex J. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004 17 : 280.
75. Peterson L, Shanholtzer C. Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance. Clin Microbiol Rev 1992 5 : 420 432.
76. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol 2002 40 : 3776 3781.
77. Walsh T, Petraitis V, Petraitiene R et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003 188 : 305 319.
78. Johnson EM, Oakley KL, Radford SA et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 2000 45 : 85 93.
79. Rex J, Pfaller M, Walsh T et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001 14 : 643 658.
80. Rex J, Pfaller M. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002 35 : 982 989.
81. Sharma O, Chwogule R. Many faces of pulmonary aspergillosis. Eur Resp J 1998 12 : 705 715.
82. Hope W, Walsh T, Denning D. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005 43 : S207 S238.
83. Zmeili O, Soubani A. Pulmonary aspergillosis: a clinical update. J Med 2007 100 : 317 334.
84. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006 50 : 1570 1572.
85. Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007 45 : 321 346.
86. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Antimicrobial Resistance 2002 35 : 1073 1080.
87. Marr KA, Seidel K, Slavin MA et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000 96 : 2055 2061.
88. Pfaller M, Rinaldi M, Diekema D. Results from the ARTEMIS DISK global antifungal surveillance study: a 6.5-year analysis of the worldwide susceptibility of yeasts to fluconazole and voriconazole using standardized disk diffusion testing. J Clin Microbiol 2005 43 : 5848 5849.
89. Pfaller M, Pappas P, Wingard J. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006 43 : 3 14.
90. Pfaller M, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007 20 : 133 163.
91. Bassetti M, Righi E, Costa A et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006 6 : 1 6.
92. Arendrup M, Garcia-Effron G, Buzina W et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother 2009 53 : 1185 1193.
93. Perlin D. Resistance to echinocandin-class antifungal drugs. Drug Resist Update 2007 10 : 121 130.
94. Lass-Florl C, Mayr A, Perkhofer S et al. The activities of antifungal agents against yeasts and filamentous fungi: assessment according to EUCAST methodology. Antimicrob Agents Chemother 2008 52 : 3637 3641.
95. Lass-Flörl C. The changing face of epidemiology of invasive fungal diseases in Europe. Mycoses 2009 52 : 197 205.
96. Lass-Flörl C, Alastruey-Izquiderdo A, Cuenca-Estrella M, Perkhofer S, Rodriguez-Tudela JL. In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2009 53 : 794 795.
97. Balajee S, Gribskov J, Hanley E, Nickle D, Marr K. Aspergillus lentulus sp. nov., a new sibling Species of A. fumigatus. Eukaryot Cell 2005 4 : 625 632.
98. Balajee S, Nickle D, Varga J, Marr K. Molecular studies reveal frequent misidentification of Aspergillus fumigatus by morphotyping. Eukaryot Cell 2006 5 : 1705 1712.
99. Denning DW, Venkateswarlu K, Oakley KL et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997 41 : 1364 1368.
100. Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997 40 : 401 414.
101. van der Linden J, Jansen R, Bresters D et al. Azole-resistant central nervous system aspergillosis. Clin Infect Dis 2009 48 : 1111 1113.
102. Verweij P, Howard DH, Melchers WJG, Denning D. Azole resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Rev 2009 (in press).
103. Ruchel R, Perske C, Glass B, Basecke J. A case of pulmonary aspergillosis with lack of response to caspofungin. Rev Iberoam Micol 2006 23 : 94 96.
104. Sahi H, Avery R, Minai O et al. Scedosporium apiospermum (Pseudoallescheria boydii) infection in lung transplant recipients. J Heart Lung Transplant 2007 26 : 350 356.
105. Bonatti H, Goegele H, Tabarelli D et al. Pseudallescheria boydii infection after liver retransplantation. Liver Transpl 2007 13 : 1068 1069.
106. Richardson C, Lass-Florl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008 14 (Suppl 4 5 24.